Literature DB >> 30288659

Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma.

Sang Yeon Cho1, Sungha Kim2, Mi-Ju Son2, Woo Sun Rou3,4, Seok Hyun Kim3,4, Hyuk Soo Eun5,6, Byung Seok Lee7,8.   

Abstract

BACKGROUND: Oxidative stress occurs due to the excessive generation of cellular reactive oxygen species and antioxidant system dysfunction. The thioredoxin (TXN) system and TXN-domain-containing protein (TXNDC) family form networks maintaining the cellular reducing environment. Recently, the importance of these genes in the tumor environment has been emphasized. AIM: To investigate the clinical significance of TXNs and TXNDC family members in HCC.
METHODS: Genomic data from 367 hepatocellular carcinoma (HCC) patients who underwent hepatic resections were analyzed to determine genetic alterations in mRNA and protein levels between patients and healthy controls. In addition, functional enrichment and survival analyses were performed.
RESULTS: HCC patients were shown to have enhanced expression of TXN, TXNRD1, and TXNDC7/9/14 mRNA and protein compared with controls. In accordance with the survival analyses, strong associations were found that patients with TXN, TXNRD1, and TXNDC1/7/9 alterations were proven to have poor prognosis in overall survival. Moreover, gene set enrichment analysis and network analyses revealed that positive correlations were found in mRNA expression of TXN, TXNRD1, and TXNDC7/9 genes with upregulation of the tumor-promoting genes, specifically mTORC1, E2F targets, and Myc targets. On the other hand, elevated expressions of TXNIP and TXNDC11 genes were correlated with suppression of the above tumor-promoting genes.
CONCLUSIONS: TXN system and TXNDC family gene panel obtained from the resected tissue of the HCC patients could be used to predict survival prognosis of HCC, and these genes could be considered as potential therapeutic targets for improving HCC survival.

Entities:  

Keywords:  Hepatocellular carcinoma; Overall survival; TXN-domain-containing protein; Thioredoxin

Mesh:

Substances:

Year:  2018        PMID: 30288659     DOI: 10.1007/s10620-018-5307-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.

Authors:  Liangliang Shen; John M O'Shea; Mohan R Kaadige; Stéphanie Cunha; Blake R Wilde; Adam L Cohen; Alana L Welm; Donald E Ayer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

2.  Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia.

Authors:  M Berggren; A Gallegos; J R Gasdaska; P Y Gasdaska; J Warneke; G Powis
Journal:  Anticancer Res       Date:  1996 Nov-Dec       Impact factor: 2.480

3.  TXNIP overexpression suppresses proliferation and induces apoptosis in SMMC7221 cells through ROS generation and MAPK pathway activation.

Authors:  Jian Li; Zhongyi Yue; Wancheng Xiong; Peisheng Sun; Kun You; Jianguo Wang
Journal:  Oncol Rep       Date:  2017-04-18       Impact factor: 3.906

Review 4.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

5.  TXNDC9 expression in colorectal cancer cells and its influence on colorectal cancer prognosis.

Authors:  Aiguo Lu; Xiongzhi Wangpu; Dingpei Han; Hao Feng; Jingkun Zhao; Junjun Ma; Shun Qu; Xuehua Chen; Bingya Liu; Minhua Zheng
Journal:  Cancer Invest       Date:  2012-12       Impact factor: 2.176

6.  Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome.

Authors:  A Mollbrink; R Jawad; A Vlamis-Gardikas; P Edenvik; B Isaksson; O Danielsson; P Stål; A P Fernandes
Journal:  Int J Immunopathol Pharmacol       Date:  2014 Apr-Jun       Impact factor: 3.219

7.  Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.

Authors:  Jun Li; Zhang-Jun Cheng; Yang Liu; Zhen-Lin Yan; Kui Wang; Dong Wu; Xu-Ying Wan; Yong Xia; Wan Yee Lau; Meng-Chao Wu; Feng Shen
Journal:  Oncotarget       Date:  2015-04-20

Review 8.  TXNDC5, a newly discovered disulfide isomerase with a key role in cell physiology and pathology.

Authors:  Elena Horna-Terrón; Alberto Pradilla-Dieste; Cristina Sánchez-de-Diego; Jesús Osada
Journal:  Int J Mol Sci       Date:  2014-12-17       Impact factor: 5.923

Review 9.  Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets.

Authors:  Zhanpeng Wang; Zhuonan Li; Yanshuo Ye; Lijuan Xie; Wei Li
Journal:  Oxid Med Cell Longev       Date:  2016-11-10       Impact factor: 6.543

10.  Overexpression of the E2F target gene CENPI promotes chromosome instability and predicts poor prognosis in estrogen receptor-positive breast cancer.

Authors:  Pulari U Thangavelu; Cheng-Yu Lin; Srividya Vaidyanathan; Thu H M Nguyen; Eloise Dray; Pascal H G Duijf
Journal:  Oncotarget       Date:  2017-07-10
View more
  9 in total

1.  Novel antibody against TMX2 and its effects on breast cancer cells.

Authors:  Eleana Hatzidaki; Dimitrios A Ntanovasilis; Ioannis Papasotiriou
Journal:  Int J Biochem Mol Biol       Date:  2020-02-15

2.  Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.

Authors:  Bin Yu; Han Liang; Qifa Ye; Yanfeng Wang
Journal:  J Gastrointest Surg       Date:  2020-03-03       Impact factor: 3.452

3.  Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress.

Authors:  Qianqian Zhang; Weiqian Chen; Xiuling Lv; Qiaoyou Weng; Minjiang Chen; Ri Cui; Guang Liang; Jiansong Ji
Journal:  Front Pharmacol       Date:  2019-10-14       Impact factor: 5.988

4.  Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  J Clin Transl Hepatol       Date:  2021-02-22

Review 5.  Modulation of ERQC and ERAD: A Broad-Spectrum Spanner in the Works of Cancer Cells?

Authors:  Gábor Tax; Andrea Lia; Angelo Santino; Pietro Roversi
Journal:  J Oncol       Date:  2019-10-01       Impact factor: 4.375

6.  miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1.

Authors:  Shengni Hua; Yingyao Quan; Meixiao Zhan; Huaxin Liao; Yong Li; Ligong Lu
Journal:  Cancer Cell Int       Date:  2019-07-30       Impact factor: 5.722

7.  Comprehensive analysis reveals a metabolic ten-gene signature in hepatocellular carcinoma.

Authors:  Zhipeng Zhu; Lulu Li; Jiuhua Xu; Weipeng Ye; Borong Chen; Junjie Zeng; Zhengjie Huang
Journal:  PeerJ       Date:  2020-05-26       Impact factor: 2.984

8.  Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting.

Authors:  Chad N Brocker; Donghwan Kim; Tisha Melia; Kritika Karri; Thomas J Velenosi; Shogo Takahashi; Daisuke Aibara; Jessica A Bonzo; Moshe Levi; David J Waxman; Frank J Gonzalez
Journal:  Nat Commun       Date:  2020-11-17       Impact factor: 14.919

9.  High expression of TXNDC11 indicated unfavorable prognosis of glioma.

Authors:  Peng Peng; Fangling Cheng; Yuting Dong; Zirong Chen; Xiaolin Zhang; Dongsheng Guo; Xingjiang Yu; Yiyang Lu; Yuyong Ke; Bin Zhang; Ximiao He; Feng Wan
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.